| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:ZLORABA PREVLADUJOČEGA POLOŽAJA V KONKURENČNEM PRAVU EU: ANALIZA PRIMERA ASTRAZENECA PROTI EVROPSKI KOMISIJI
Authors:ID Bečan, Domen (Author)
ID Tratnik, Matjaž (Mentor) More about this mentor... New window
Files:.pdf UNI_Becan_Domen_2013.pdf (569,42 KB)
MD5: 4E50559C7FE56D75F583BB1404B76307
 
Language:Slovenian
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:PF - Faculty of Law
Abstract:Diplomska naloga se ukvarja z institutom zlorabe prevladujočega položaja v luči primera AstraZeneca proti Evropski Komisiji. Predstavljena je uporaba tega instituta v farmacevtskem sektorju, za katerega veljajo določene posebnosti. Poleg tega je pozornost namenjena tudi ugotovitvam Splošnega sodišča v zvezi z uporabo patentne strategije AstraZenece ter uporabo strategije glede regulatorne zaščite podatkov v zvezi z zdravili. Obe predstavljata novi obliki protikonkurenčnega ravnanja oziroma zlorabe prevladujočega položaja. Diplomska naloga je razdeljena na dva dela. V prvem delu so predstavljena teoretična izhodišča, ki so potrebna za razumevanje sodne odločbe. Na prvem mestu je tu predstavljen institut zlorabe prevladujočega položaja, in sicer, kako je urejen v pravu EU ter kakšno vsebino je dalo Sodišče EU posameznim konceptom, povezanim s tem institutom. Nato je v tem delu predstavljeno razmerje med pravom intelektualne lastnine in pravom konkurence, zlasti razmerje med PIL in členom 102 PDEU. Poleg tega pa je v tem delu predstavljena tudi pravna ureditev farmacevtskega sektorja, predvsem njegove posebne značilnosti nasproti drugim gospodarskim sektorjem. Te posebnosti so način financiranja zdravil, način določanja cen, posebno dovoljenje, potrebno za promet z zdravili, vzporeden uvoz zdravil, dodatni varstveni certifikat ter patentna in regulatorna zaščita farmacevtskih proizvodov. V drugem delu pa se diplomska naloga ukvarja s sodbo v primeru AstraZeneca. Pri tem so predstavljene ugotovitve Splošnega sodišča glede upoštevnega trga, prevladujočega položaja ter prve in druge očitane zlorabe. Pri upoštevnem trgu je izpostavljena problematika ozke razlage tega trga. V zvezi z očitanima zlorabama pa je Splošno sodišče presojalo, ali je način pridobitve dodatnega varstvenega certifikata v skladu s pravili o konkurenci in ali menjava izdelkov ter umik dovoljenja za promet za starejše produkte pomeni protikonkurenčno ravnanje. Na koncu diplomske naloge so predstavljene še posledice in pomen sodbe, ki ga ta ima na nadaljnji razvoj farmacevtskega sektorja.
Keywords:Zloraba prevladujočega položaja, farmacevtski sektor, upoštevni trg, dodatni varstveni certifikat, pravice intelektualne lastnine, regulatorna zaščita, generična zdravila.
Place of publishing:Maribor
Publisher:[D. Bečan]
Year of publishing:2013
PID:20.500.12556/DKUM-43152 New window
UDC:339.137:339.923:061.1EU(043.2)
COBISS.SI-ID:4601387 New window
NUK URN:URN:SI:UM:DK:C1TWDQX2
Publication date in DKUM:10.01.2014
Views:2342
Downloads:267
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Categories:PF
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Secondary language

Language:English
Title:ABUSE OF DOMINANCE IN EU COMPETITION LAW: LEGAL ANALYSIS OF ASTRAZENECA V. EUROPEAN COMMISSION CASE
Abstract:The issue of this diploma work focuses on abuse of dominance in the light of AstraZeneca v. European Commission case. In this work is presented the application of Article 102 TFEU in the pharmaceutical sector which has some special characteristics. The attention is also focused on General Court's findings about the AstraZeneca's use of patent and regulatory data protection strategy. Both present new ways of abusing dominant position in the pharmaceutical sector. The work is divided into two parts. In the first part are presented the theoretical backgrounds, necessary for understanding of General Court's decisions in this case. It consists of the regulation of abuse of dominance in EU Competition Law, specially particular concepts dealing with Article 102 TFEU, which were explained through the case law of European Court. This part also deals with the Intellectual Property Rights and Competition Law interface, specially with the relation between IPR and Article 102 TFEU. Here is also presented the regulation of pharmaceutical sector with its special characteristics in EU. Such special characteristics are the way of financing drugs and determinating its prices, parallel import of drugs, patent and regulatory protection, market authorization, supplementary protection certificate and so on. The issue of the second part of this diploma work is the analysis of the AstraZeneca case. In this part are presented General Court's findings about relevant market, dominant position, first and second abuse. The determination of relevant market is also subject to the problems with narrow market definition. As for the first and second abuse, General Court dealt with regulatory and patent strategy of AstraZeneca, whether the way of acquiring Supplementary Protection Certificate and changing the older version of the drug with its new equivalent was suitable with EU Competition Law or not and if this behaviour was anticompetitive. In the end are also presented some thoughts about the consequences of the General Court's decision.
Keywords:Abuse of dominance, pharmaceutical sector, relevant market, supplementary protection certificate, intellectual property rights, regulatory data protection, generic drugs.


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica